PMID- 21468754
OWN - NLM
STAT- MEDLINE
DCOM- 20111121
LR  - 20211203
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 6
IP  - 2
DP  - 2011 Jun
TI  - Mammalian target of rapamycin expression in poorly differentiated endocrine 
      carcinoma: clinical and therapeutic future challenges.
PG  - 65-8
LID - 10.1007/s11523-011-0171-z [doi]
AB  - While the mammalian target of rapamycin (mTOR) signaling pathway is a promising 
      target for well-differentiated endocrine carcinoma therapy with the mTOR 
      inhibitor everolimus (RAD001), poorly differentiated endocrine carcinomas (PDECs) 
      are usually excluded from clinical trials due to their aggressiveness. So far, 
      mTOR activity in PDECs has only been tested in cell lines. This study reviewed 36 
      mono-institutional PDECs to determine mTOR expression. Slides of normal kidney as 
      positive control were used to optimize mTOR staining. To ensure antibody 
      specificity, consecutive sections were incubated in the absence of primary 
      antibody. Immunoreactivity was evaluated on a semi-quantitative scale scoring the 
      extent and intensity of staining. The product of these two scores was used to 
      obtain a total immunostaining score. The main primary site of disease was the 
      pancreas, and 83% of patients had stage IV disease. In 80% of samples, mTOR 
      expression was maintained at similar levels, with no relationship to tumor origin 
      or proliferation rate determined by MIB-1. This study seems to demonstrate that 
      mTOR is expressed in human PDECs regardless of tumor site. Its role in relation 
      to the activity of everolimus in this subset of patients needs to be confirmed.
FAU - Catena, Laura
AU  - Catena L
AD  - Istituto di Oncologia, Policlinico di Monza, Via C. Amati, Monza, MB, Italy. 
      laura.catena@policlinicodimonza.it
FAU - Bajetta, Emilio
AU  - Bajetta E
FAU - Milione, Massimo
AU  - Milione M
FAU - Ducceschi, Monika
AU  - Ducceschi M
FAU - Valente, Monica
AU  - Valente M
FAU - Dominoni, Francesca
AU  - Dominoni F
FAU - Colonna, Valentina
AU  - Colonna V
LA  - eng
PT  - Journal Article
DEP - 20110406
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Protein Kinase Inhibitors)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Cell Line, Tumor
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Molecular Targeted Therapy/methods
MH  - Neuroendocrine Tumors/drug therapy/*metabolism
MH  - Prognosis
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Signal Transduction
MH  - Sirolimus/analogs & derivatives/therapeutic use
MH  - TOR Serine-Threonine Kinases/*biosynthesis
MH  - Young Adult
EDAT- 2011/04/07 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/04/07 06:00
PHST- 2010/11/19 00:00 [received]
PHST- 2011/03/09 00:00 [accepted]
PHST- 2011/04/07 06:00 [entrez]
PHST- 2011/04/07 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1007/s11523-011-0171-z [doi]
PST - ppublish
SO  - Target Oncol. 2011 Jun;6(2):65-8. doi: 10.1007/s11523-011-0171-z. Epub 2011 Apr 
      6.